SpringWorks Therapeutics (SWTX, Financial) is under the spotlight as its product, Ogsiveo, has been added to the agenda of the Committee for Medicinal Products for Human Use. This advancement indicates that Ogsiveo could soon receive a positive opinion, potentially leading to regulatory approval in the European Union.
Such an approval could play a pivotal role in reducing uncertainties surrounding the company, potentially paving the way for an acquisition by Merck KGaA. An industry analyst has reinforced this viewpoint, assigning an Overweight rating to SpringWorks with a price target of $63 per share, suggesting confidence in the company's growth potential amidst these developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for SpringWorks Therapeutics Inc (SWTX, Financial) is $72.50 with a high estimate of $84.00 and a low estimate of $63.00. The average target implies an upside of 86.33% from the current price of $38.91. More detailed estimate data can be found on the SpringWorks Therapeutics Inc (SWTX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, SpringWorks Therapeutics Inc's (SWTX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
